How are energy investors positioned?
MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on epilepsy treatment, saw its shares rise 5% after reporting better-than-expected fourth quarter results and providing an optimistic outlook for 2025.
The company reported Q4 adjusted earnings per share of -$0.18, surpassing analyst estimates of -$0.25. Revenue for the quarter came in at $21.5 million, exceeding the consensus projection of $20.91 million and representing a 19% YoY increase.
NeuroPace’s full-year 2024 revenue grew 22% to $79.9 million. For 2025, the company forecasts revenue between $92 million and $96 million, in line with analyst expectations of $92.96 million.
CEO Joel Becker commented, "We are pleased with the strong revenue growth reported in 2024, as we continue to implement our long-range plan aimed at expanding access to and indications for the RNS System."
The company’s gross margin for Q4 2024 improved slightly to 75.4% from 75.2% in the same period last year. Operating expenses increased to $19.8 million from $18.6 million in Q4 2023, primarily due to higher R&D and sales and marketing costs.
NeuroPace recently completed a public offering, raising $74.8 million. The company used $49.5 million to repurchase shares from KCK Ltd. and allocated $20.2 million to strengthen its balance sheet.
The 5% stock rise following the earnings release suggests investors are responding positively to NeuroPace’s financial performance and future outlook. The company remains focused on expanding its RNS System for epilepsy treatment and advancing several product development programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.